Angiochem Named as One of the “Fierce 15” Biotech Companies of 2012

Angiochem Named as One of the “Fierce 15” Biotech Companies of 2012

, a clinical stage biotechnology company, was named by FierceBiotech today as one of 2012’s Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's tenth annual Fierce 15 selection.

“Angiochem stands out because its drugs do or seek to do what a minority of existing treatments accomplish—penetrate the blood-brain barrier,” says FierceBiotech Executive Editor Ryan McBride. “The company’s internal programs and viable partnerships with GlaxoSmithKline and Geron offer many potential treatments for diseases that affect the brain.”

“Angiochem is honored to be named a Fierce 15 biotech company in recognition of the demonstrated ability of our EPiC platform technology to penetrate brain tissue to address CNS diseases which have previously been insurmountable due to the fundamental physiological challenge posed by the blood brain barrier. By leveraging the LRP-1 mediated pathway, Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and lysosomal storage diseases, pain, and others,” said Jean Paul Castaigne, MD, President and CEO of Angiochem.

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition.

An internationally recognized daily newsletter reaching more than 100,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

The 2012 Fierce 15 companies will be recognized today at the BioPharm America conference in Boston. A complete list of "Fierce 15" companies – the online newsletter's ninth annual selection – is available online at .

Angiochem’s Engineered Peptide Compound (EPiC) Technology is the proven platform behind a new class of highly innovative and effective pharmaceuticals that address unmet medical needs involving brain diseases and CNS-related disorders. One of Angiochem's EPiC-derived drugs is in development for treatment of brain tumors and is achieving clinically meaningful outcomes. Based on proprietary sequences of amino acids, called Angiopeps, which are engineered to specifically target the LRP-1 receptor, the EPiC technology platform is highly versatile and applicable to a range of therapeutic areas.

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new EPiC compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and lysosomal storage diseases, pain, and others. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit .

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at .

Suggested Articles

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.